Stockscreener 앱 받기
3.695
31.67%
0.885
전일 마감가:
$2.81
열려 있는:
$3.59
하루 거래량:
68.61M
Relative Volume:
31.13
시가총액:
$307.02M
수익:
-
순이익/손실:
$-36.95M
주가수익비율:
-4.3988
EPS:
-0.84
순현금흐름:
$-33.46M
1주 성능:
+22.11%
1개월 성능:
+0.27%
6개월 성능:
-5.37%
1년 성능:
+22.11%
1일 변동 폭
$3.55
$4.01
1주일 범위
$2.715
$4.01
52주 변동 폭
$1.61
$5.37
Larimar Therapeutics Inc Stock (LRMR) Company Profile
명칭
Larimar Therapeutics Inc
전화
844-511-9056
주소
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Compare LRMR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
3.695 | 233.48M | 0 | -36.95M | -33.46M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
487.60 | 122.19B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
772.33 | 83.21B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
837.67 | 51.13B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.52 | 43.68B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
368.65 | 41.01B | 4.98B | 69.60M | 525.67M | 0.5198 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-29 | 개시 | Truist | Buy |
| 2024-10-16 | 개시 | Oppenheimer | Outperform |
| 2024-10-03 | 개시 | Wedbush | Outperform |
| 2024-10-02 | 개시 | H.C. Wainwright | Buy |
| 2024-09-04 | 개시 | Robert W. Baird | Outperform |
| 2024-04-03 | 개시 | Leerink Partners | Outperform |
| 2023-11-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-10-19 | 개시 | Guggenheim | Buy |
| 2022-02-15 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-02-10 | 개시 | JMP Securities | Mkt Outperform |
| 2021-02-01 | 개시 | William Blair | Outperform |
모두보기
Larimar Therapeutics Inc 주식(LRMR)의 최신 뉴스
Biotech and Big Tech Drive the Morning Narrative - Investing News Network
Tuesday Sector Leaders: Biotechnology, Semiconductors - Nasdaq
Larimar Therapeutics (LRMR) Surges On FDA Breakthrough Therapy Designation - Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Larimar Soars After FDA Grants Breakthrough Therapy Status To Friedreich's Ataxia Candidate - Nasdaq
Larimar Therapeutics Stock Surges Following Impressive Financial Indicators - StocksToTrade
Larimar Therapeutics jumps on FDA Breakthrough Therapy Designation for nomlabofusp - Quiver Quantitative
Larimar Therapeutics stock surges on FDA breakthrough status By Investing.com - Investing.com South Africa
Larimar Therapeutics stock surges on FDA breakthrough status - Investing.com UK
Larimar Therapeutics’ Recent Stock Trends and Financial Insights - timothysykes.com
Larimar Therapeutics (LRMR) Surges on FDA Breakthrough Designati - GuruFocus
Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? - Stocktwits
Larimar Therapeutics' Friedreich's Ataxia Therapy Receives FDA Breakthrough Status; Shares Rise - marketscreener.com
Larimar Therapeutics shares surged 35.6% in pre-market trading after the company announced that its treatment for a neurological disease had received “Breakthrough Therapy” designation from the U.S. Food and Drug Administration (FDA). - Bitget
Larimar stock surges on FDA breakthrough status (LRMR:NASDAQ) - Seeking Alpha
FDA Grants Breakthrough Therapy Status to Larimar’s Nomlabofusp - TipRanks
Larimar Therapeutics announces FDA Breakthrough Therapy Designation for nomlabofusp - marketscreener.com
Larimar Therapeutics wins FDA Breakthrough Therapy Designation for nomlabofusp; BLA on track for June 2026 - TradingView
Larimar Therapeutics Announces FDA Breakthrough Therapy - GlobeNewswire
IPO Launch: Can Larimar Therapeutics Inc beat the S P 500July 2025 Breakouts & Fast Moving Stock Trade Plans - baoquankhu1.vn
Forecast Cut: Is Larimar Therapeutics Inc being accumulated by smart moneyJuly 2025 Weekly Recap & Short-Term High Return Ideas - baoquankhu1.vn
Is Larimar Therapeutics Inc. impacted by rising ratesCEO Change & Detailed Earnings Play Strategies - mfd.ru
Does Larimar Therapeutics Inc. have consistent dividend growthDollar Strength & Daily Entry Point Trade Alerts - mfd.ru
Investor Mood: Is Larimar Therapeutics Incs growth already priced in2025 Market Trends & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Is Larimar Therapeutics Inc. being accumulated by smart moneyQuarterly Portfolio Summary & Verified Technical Trade Signals - mfd.ru
Does Larimar Therapeutics Inc. have a sustainable dividendWeekly Investment Report & Smart Investment Allocation Insights - mfd.ru
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Gap Down: Will Larimar Therapeutics Inc benefit from geopolitical trendsJuly 2025 Drop Watch & Consistent Return Strategy Ideas - baoquankhu1.vn
Guidance Update: Does Larimar Therapeutics Inc have consistent dividend growthJuly 2025 Setups & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Geopolitics Watch: Is Larimar Therapeutics Inc. being accumulated by smart money2025 Price Momentum & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Portfolio Update: Is Smith Douglas Homes Corp a cyclical or defensive stockQuarterly Risk Review & Verified Short-Term Trading Plans - baoquankhu1.vn
Larimar Therapeutics executes strategic stock exchange agreement - MSN
Larimar’s Pediatric Friedreich’s Ataxia Trial Termination: What Investors Should Know - TipRanks
Friedreich's Ataxia Pipeline 2025: FDA Approvals and Clinical - openPR.com
AIGH Capital Management LLC Takes $3.23 Million Position in Larimar Therapeutics, Inc. $LRMR - MarketBeat
We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully - Sahm
Head-To-Head Survey: Oncology Pharma (OTCMKTS:ONPH) vs. Larimar Therapeutics (NASDAQ:LRMR) - Defense World
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Larimar Therapeutics: The Market Is Mispricing A Potential Standard Of Care (NASDAQ:LRMR) - Seeking Alpha
Aug Gainers: What risks investors should watch in Larimar Therapeutics Inc stockQuarterly Profit Summary & Low Risk Entry Point Guides - Bộ Nội Vụ
Published on: 2026-01-14 08:49:57 - Bộ Nội Vụ
Death Cross: How Larimar Therapeutics Inc stock performs during Fed tightening cyclesM&A Rumor & Risk Adjusted Buy and Sell Alerts - Bộ Nội Vụ
Published on: 2026-01-13 20:02:33 - Bộ Nội Vụ
Aug Intraday: Will Larimar Therapeutics Inc. stock outperform value stocks2025 Technical Patterns & Risk Adjusted Buy/Sell Alerts - Bộ Nội Vụ
Published on: 2026-01-13 12:38:02 - moha.gov.vn
Volatility Watch: Does Larimar Therapeutics Inc have a sustainable dividendTrade Risk Assessment & AI Forecast Swing Trade Picks - baoquankhu1.vn
Will Larimar Therapeutics Inc. stock outperform value stocksTrade Volume Summary & Pattern Based Trade Signal System - ulpravda.ru
Contact | Statesman-ExaminerLarimar Therapeutics, Inc.Common Stock (Nasdaq:LRMR) Detailed Stock Data - FinancialContent
Why Larimar Therapeutics Inc. stock remains resilientRate Cut & AI Powered Market Entry Strategies - Улправда
Larimar Therapeutics Advances Friedreich’s Ataxia Program with New Publications on Nomlabofusp Data - MSN
Larimar Therapeutics Inc (LRMR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.29%
0.15%
자본화:
|
볼륨(24시간):